Efficacy of Oral Antiobesity Medications With Versus Without Adjunct Behavioral Weight Management Treatment
Obesity · 2026
DOI: 10.1002/oby.70127 ↗At a glance
Randomisierte kontrollierte Studie in Obesity, 2026. Written by Rebecca A Jones and 11 co-authors. Institution: WW International Inc., New York, New York, USA. Major MEDLINE topics: Obesity, Anti-Obesity Agents, Behavior Therapy, Bupropion. 31 references. Funded by: WW International Inc..
Abstract (original language)
Objective
Guidelines recommend pairing antiobesity medications (AOMs) with behavioral treatment. This 12‐week, two‐arm randomized controlled trial evaluated oral AOMs with versus without behavioral treatment.
Methods
We recruited 101 patients eligible for bupropion and naltrexone from a telehealth weight management clinic (WeightWatchers Clinic). Participants were randomized to (i) bupropion and naltrexone ( n = 50) or (ii) bupropion and naltrexone with behavioral treatment (WeightWatchers) ( n = 51). Remote measurements of body weight, behavioral, and psychosocial measures were completed at baseline and week 12. The primary outcome was the 12‐week change in weight (kg). ANCOVA assessed differences in changes between groups.
Results
Participants ( n = 101) were mostly female (94.1%), average 43.9 years old (SD: 10.7), with a mean BMI of 37.0 kg/m 2 (SD: 6.3). At 12 weeks, those receiving behavioral treatment lost significantly more absolute and percent weight than those without behavioral treatment (mean difference: −1.8 kg, p = 0.03; mean difference: −1.6%, p = 0.04).
Conclusions
Combining oral AOMs with behavioral treatment via telemedicine resulted in significantly greater weight loss than medications alone, supporting the recommendation to pair AOMs with behavioral treatment. Trial Registration ClinicalTrials.gov identifier: NCT06470659
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- WW International Inc., New York, New York, USA.
- Center for Weight and Eating Disorders, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Department of Family and Preventive Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
- Department of Pharmaceutical Outcomes and Policy, University of Florida, College of Pharmacy, Gainesville, Florida, USA.
- Center for Integrative Cardiovascular and Metabolic Disease, University of Florida, Gainesville, Florida, USA.
ORCID profiles: Gary D Foster, Young-Rock Hong, Kelli M Richardson, Michelle I Cardel
Funding
- WW International Inc.
Cite
APA
Jones, R. A., Lee, A. M., Foster, G. D., Nadolsky, S., Killion, K., Gentry, L. N., Zeldman, J., Hong, Y. R., Medcalf, A., Estes, F., Richardson, K. M., & Cardel, M. I. (2026). Efficacy of Oral Antiobesity Medications With Versus Without Adjunct Behavioral Weight Management Treatment. Obesity. https://doi.org/10.1002/oby.70127
Vancouver
Jones RA, Lee AM, Foster GD, Nadolsky S, Killion K, Gentry LN, et al. Efficacy of Oral Antiobesity Medications With Versus Without Adjunct Behavioral Weight Management Treatment. Obesity. 2026. doi:10.1002/oby.70127
BibTeX
@article{Jones2026,
author = {Jones, Rebecca A and Lee, Alexandra M and Foster, Gary D and Nadolsky, Spencer and Killion, Kate and Gentry, Lela N and Zeldman, Jamie and Hong, Young-Rock and Medcalf, Adam and Estes, Forrest and Richardson, Kelli M and Cardel, Michelle I},
title = {Efficacy of Oral Antiobesity Medications With Versus Without Adjunct Behavioral Weight Management Treatment},
journal = {Obesity},
year = {2026},
doi = {10.1002/oby.70127}
}
EUVIMED